Company Profile
Arbutus Stock Price, News & Analysis
- Ticker:
- ABUS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
4.54 USD (-1.73%)
Close
Last updated: August 6, 2026
842M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ABUS closed down 1.73% at $4.54. No new same-company headline was identified in the current news window.
Company overview
Hepatitis B Therapeutics Company
Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B.
Imdusiran
Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens.
Combination Strategy
The company’s development approach pairs viral antigen suppression with immune-modulating agents to seek durable off-treatment control.
Genevant Economics
Arbutus also retains economic exposure to lipid nanoparticle intellectual property through Genevant and related licensing and litigation arrangements.
Future catalysts
What matters most for Arbutus from here is imdusiran. That matters because the company is now talking about continued work around imdusiran and the next company-specific development update. That is the piece most likely to shape sentiment in the near term.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arbutus (ABUS)?
Arbutus (ABUS) most recently closed at 4.54 USD, a -1.73% move versus the previous session.
What is the market cap of Arbutus (ABUS)?
Arbutus currently has a market capitalization of 842M USD on BioPharmSignal.
What does Arbutus do?
Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens. Combination Strategy The...
On which exchange is ABUS stock listed?
Arbutus (ABUS) is associated with NASDAQ, Canada, Biopharma.
What is Hepatitis?
Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B.
Which conditions is Arbutus targeting with Hepatitis?
Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens. Combination Strategy The...
How does Arbutus describe recent progress with Hepatitis?
What matters most for Arbutus from here is imdusiran. That matters because the company is now talking about continued work around imdusiran and the next company-specific development update. That is the piece most likely to shape sentiment in the near term.
What is Therapeutics?
Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B.